11th Dec 2019 10:56
(Alliance News) - US clinical-stage pharma firm Verseon Corp said Wednesday 29% of its tender offer shares have been validly tendered, costing about USD127,000.
In November, Verseon said it was hoping to buy back up to 21.4 million shares, about 13% of the total outstanding, in a tender offer.
On Wednesday, the company said it bought back 6.1 million, about 3.8% of its issued share capital, at 1.56 pence each, for a total of around GBP95,764.
The company was trading down 5.1% in London on Wednesday at 1.40p.
Verseon will de-list from London's AIM following approval at a shareholder meeting last Friday. The company's shares will be removed from London's junior market on December 19, next Thursday.
By Paul McGowan; [email protected]
Copyright 2019 Alliance News Limited. All Rights Reserved.